Subscribe To
ACIU / Trading Penny Stocks With Limited Capital: 3 Tops Tips
ACIU News
By Zacks Investment Research
October 24, 2023
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
October 20, 2023
AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the k more_horizontal
By Zacks Investment Research
September 5, 2023
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for more_horizontal
By GlobeNewsWire
September 5, 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 more_horizontal
By Zacks Investment Research
August 4, 2023
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share more_horizontal
By The Motley Fool
June 30, 2023
Why Shares of AC Immune Jumped This Week
AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an Alzheimer's disease vaccine. more_horizontal
By PennyStocks
June 28, 2023
Trading Penny Stocks With Limited Capital: 3 Tops Tips
The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially t more_horizontal
By Market Watch
June 27, 2023
AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment
AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration f more_horizontal